Predictmedix Announces US Patent Grant
for AI-Powered Impairment Detection Technology for Cannabis and
Alcohol Screening
Toronto, Ontario - March 21, 2023 -
InvestorsHub NewsWire -- Predictmedix Inc. ("Predictmedix" or the
"Company") (CSE: PMED) (OTCQB: PMEDF) (FRA:3QP), a leading provider of rapid
health screening solutions powered by proprietary artificial
intelligence (AI), announced today that the US Patent Office has
granted a patent for its AI-powered technology (United States
Patent Application Number: 16/892,369) for the non-invasive
detection of impairment caused by alcohol and/or
cannabis.
The patented technology uses
multispectral imaging and speech analysis to identify and extract
features from an individual, allowing the technology to determine
whether the individual is exhibiting signs associated with
impairment. The technology is part of the Company's Fit for Duty
screening solutions, which provide contactless and bias-free
screening for impairment, extreme fatigue, and infectious
diseases.
The Safe Entry is a walk-thru system
which uses a multispectral imaging camera and AI computing to
gather key physiological information in just 2-3 seconds to
determine an individual's physiological state. Unlike urine and
breathalyzer tests, Safe Entry is contactless, which means no
biological fluids are taken. Safe Entry is powered by AI and ML
algorithms, which give individuals a fair and accurate assessment
of their physiological state.
"The patent grant for our impairment
screening technology is yet another milestone for Predictmedix,"
said Dr. Rahul Kushwah, Chief Operating Officer at Predictmedix.
"Our proprietary technology has the potential to revolutionize the
way that businesses and organizations screen for impairment. We
have a lot of exciting opportunities in our pipeline and being to
be at the forefront of this scientific AI breakthrough and
providing proven, accurate solutions to combat impairment is a top
priority for Predictmedix. Our team is dedicated to continuing to
innovate and improve our technology to provide our clients with the
most effective and efficient solutions. With the grant of this
patent, we have strengthened our position as a leader in the health
screening industry and we are excited to continue to expand our
offerings and make a positive impact on workplaces and
organizations around the world."
The global workplace safety market was
valued at $12.8 billion in 2021, and is projected to reach $39
billion by 2031, growing at a CAGR of 12.2% from 2022 to
20311
while the Drug Screening market size
is expected to grow at a CAGR of 15.97% from 2022 to 2029, reaching
nearly USD $22.24 billion.2
1
https://www.alliedmarketresearch.com/workplace-safety-market-A31780
2 https://www.emergenresearch.com/industry-report/drug-screening-market
About Predictmedix Inc.
Predictmedix (CSE: PMED) (OTCQB:
PMEDF) (FRA:3QP) is an emerging provider of rapid health screening
and remote patient care solutions globally. The Company's Safe
Entry Stations – powered by a proprietary artificial intelligence
(AI) – use multispectral cameras to analyze physiological data
patterns and predict a variety of health issues including
infectious diseases such as COVID-19, impairment by drugs or
alcohol, fatigue or various mental illnesses. Predictmedix's
proprietary remote patient care platform empowers medical
professionals with a suite of AI-powered tools to improve patient
health outcomes. To learn more, please visit our website at
www.Predictmedix.com or follow us on Twitter, Instagram or
LinkedIn.
Public Relations Contact
For further media information or to
set up an interview, please contact:
Nelson Hudes
Hudes Communications
International
(905) 660 9155
Nelson@hudescommunications.com
Dr. Rahul Kushwah
(647) 889 6916
Caution Regarding Forward-Looking
Information:
This news release may contain
forward-looking statements and information based on current
expectations. These statements should not be read as guarantees of
future performance or results of the Company. Such statements
involve known and unknown risks, uncertainties and other factors
that may cause actual results, performance or achievements to be
materially different from those implied by such statements.
Although such statements are based on management's reasonable
assumptions, there can be no assurance that such assumptions will
prove to be correct. We assume no responsibility to update or
revise them to reflect new events or circumstances. The Company's
securities have not been registered under the U.S. Securities Act
of 1933, as amended (the "U.S. Securities Act"), or applicable
state securities laws, and may not be offered or sold to, or for
the account or benefit of, persons in the United States or "U.S.
Persons", as such term is defined in Regulations under the U.S.
Securities Act, absent registration or an applicable exemption from
such registration requirements. This press release shall not
constitute an offer to sell or the solicitation of an offer to buy
nor shall there be any sale of the securities in the United States
or any jurisdiction in which such offer, solicitation or sale would
be unlawful. Additionally, there are known and unknown risk factors
which could cause the Company's actual results, performance or
achievements to be materially different from any Page 4 of 4 future
results, performance or achievements expressed or implied by the
forward-looking information contained herein, such as, but not
limited to dependence on obtaining regulatory approvals; the
ability to obtain intellectual property rights related to its
technology; limited operating history; general business, economic,
competitive, political, regulatory and social uncertainties, and in
particular, uncertainties related to COVID-19; risks related to
factors beyond the control of the Company, including risks related
to COVID-19; risks related to the Company's shares, including price
volatility due to events that may or may not be within such party's
control; reliance on management; and the emergency of additional
competitors in the industry.
All forward-looking information herein
is qualified in its entirety by this cautionary statement, and the
Company disclaims any obligation to revise or update any such
forward-looking information or to publicly announce the result of
any revisions to any of the forward-looking information contained
herein to reflect future results, events or developments, except
required by law.
Disclaimer: "The Company is not making
any express or implied claims that its product has the ability to
diagnose, eliminate, cure or contain the COVID-19 (or SARS-2
Coronavirus) at this time."
THE CANADIAN SECURITIES EXCHANGE HAS
NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE
ADEQUACY OR ACCURACY OF THIS
RELEASE.